Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs) - 05/11/12
Corresponding author. Tel.: +86 28 85422870; fax: +86 28 85424110.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background and objective |
Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GISTs). To evaluate the efficacy and safety of two dose of imatinib treatment for patients with GISTs, a meta-analysis was performed.
Methods |
Electronic search of the PubMed and EMBASE, which have articles published between 1980 and February 2012, was conducted to select studies for this meta-analysis.
Results |
Five articles with a total number 1861 of advanced GISTs patients were involved in this meta-analysis. There was a slight but significant 2-year PFS advantage with high-dose group (OR=1.25, 95% CIs=1.03–1.52, P=0.03), but not in the 2-year OS (OR=1.02, 95% CIs=0.84–1.24, P=0.87), CR (OR=1.02, 95% CIs=0.66–1.58, P=0.93), and PR (OR=1.13, 95% CIs=0.94–1.36, P=0.20). In safety, the high-dose group increased the incidence of above grade 3 toxicity (OR=2.05, 95% CIs=1.70–2.48, P<0.00001), particular in the blood toxicity, skin disorders, nausea and so on.
Conclusions |
This analysis confirms a slight 2-year PFS advantage of high-dose imatinib, but imatinib dose escalation could not lead to any other major clinical benefits, and brought more toxic effects for patients.
Le texte complet de cet article est disponible en PDF.Plan
Vol 36 - N° 5
P. 484-490 - octobre 2012 Retour au numéro
Article précédent
- Aberrant expression of Wnt and Notch signal pathways in Barrett’s esophagus
- Xia Chen, Ke Jiang, Zhining Fan, Zheng Liu, Ping Zhang, Liduan Zheng, Na Peng, Jingjing Tong, Guozhong Ji
- Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: A promising marker in predicting disease severity
- Serkan Torun, Bilge Demirel Tunc, Burak Suvak, Hakan Yildiz, Adnan Tas, Abdurrahim Sayilir, Yasemin Ozin Ozderin, Yavuz Beyazit, Ertugrul Kayacetin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?